Ixekizumab
Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60. It has been found effective in chronic plaque psoriasis as well as genital, hair...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Формат: | Ном |
| Хэвлэсэн: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
| Нөхцлүүд: | |
| Онлайн хандалт: | Connect to this object online. |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
| Зохиогчийн тэмдэгт: |
A1234.567 |
|---|---|
| Хуулбар 1 | Бэлэн |